Anti-HDAC8 antibody

Anti-HDAC8 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to HDAC8

WB

Human HDAC8

2610007D20Rik antibody; CDA07 antibody; HD8 antibody; HD8 antibody; HDAC8 antibody; HDAC8 antibody; HDACL1 antibody; RP23-331B22.1 antibody; RPD3 antibody; RPD3 antibody; HD8 antibody; WTS antibody; CDA07 antibody; CDLS5 antibody; MRXS6 antibody; HDACL1 antibody; 2610007D20Rik antibody

Rabbit IgG

Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human HDAC8, and purified by antigen affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein which belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It expressed at higher level in heart, brain, kidney and pancreas and also in liver, lung, placenta, prostate and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3 and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.

• Buggy JJ. et al.,2000, Biochem J. 350 (1): 199-205.
• Krennhrubec K. et al., 2007, Bioorg Med Chem Lett. 17 (10): 2874-8.
• Oehme I. et al., 2009, Expert Opin Investig Drugs.18 (11): 1605-17.